Marc Blaustein
Plus aucun poste en cours
Fortune : 2 426 $ au 31/03/2024
Profil
Marc B.
Blaustein is the founder of Akashi Therapeutics Inc, which was founded in 2011.
He held the title of Chief Executive Officer from 2011 to 2017.
Mr. Blaustein's former jobs include being the Chief Executive Officer of Ned Biosystems, Inc. from 2017 to 2019, Head of Business Development at Genetics Institute LLC, Senior Vice President of Manufacturing, Process & Commercial Operations at Dyax Corp.
from 2006 to 2009, Chief Operating, Financial & Accounting Officer at Finch Therapeutics Group, Inc. from 2022 to 2023, and Head of Business Development at Guide Therapeutics, Inc. from 2019 to 2021.
He is also a Founding Partner at Northbridge Consulting.
Mr. Blaustein's education includes a graduate degree from Harvard University and an undergraduate degree from the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/04/2023 | 933 ( 0,06% ) | 2 426 $ | 31/03/2024 |
Anciens postes connus de Marc Blaustein
| Sociétés | Poste | Fin |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Director of Finance/CFO | 15/05/2023 |
Guide Therapeutics, Inc.
 Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Corporate Officer/Principal | 01/01/2021 |
Ned Biosystems, Inc.
 Ned Biosystems, Inc. BiotechnologyHealth Technology Ned Biosystems, Inc. is a clinical-stage company based in Cambridge, MA. The company is focused on developing cancer treatments with the goal of providing uncommon therapies that help patients achieve "No Evidence of Disease." | Chief Executive Officer | 01/01/2019 |
Akashi Therapeutics Inc
 Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Chief Executive Officer | 01/01/2017 |
| DYAX CORP. | Corporate Officer/Principal | 01/01/2009 |
Formation de Marc Blaustein
| Harvard University | Graduate Degree |
| University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Health Technology |
Ned Biosystems, Inc.
Ned Biosystems, Inc. BiotechnologyHealth Technology Ned Biosystems, Inc. is a clinical-stage company based in Cambridge, MA. The company is focused on developing cancer treatments with the goal of providing uncommon therapies that help patients achieve "No Evidence of Disease." | Health Technology |
| Finch Therapeutics Group, Inc. | |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Health Technology |
| Northbridge Consulting |
